Instalab
logoInstalab

NT-proBNP

Blood Test
A signal of heart strain that helps assess unexplained breathlessness and future heart failure risk.
4.9 (2,251 reviews)
Tested by Quest or Access Medical
Physician-reviewed results
Results in under 1 week
How it works
Order from Instalab
No prescription or your own doctor's order needed
Get blood drawn
At home or at 2,000+ patient service centers
Get results
Explained with clear next steps, no medical jargon

Should you take a NT-proBNP test?

This test is most useful if any of these apply to you.

Living With Heart or Kidney Disease
This marker can help assess heart failure risk or prognosis, with kidney function included in the interpretation.
Living With Diabetes
Testing can identify higher heart failure risk before symptoms and help determine whether heart imaging is warranted.
Managing High Blood Pressure
Persistent high blood pressure raises heart failure risk; this test can add information about strain on your heart.
Getting Winded More Easily
Testing can help assess unexplained breathlessness, though a low result can miss heart failure, especially with obesity.

About NT-proBNP

NT-proBNP can rise before heart failure causes symptoms. In large studies following adults without heart failure at the start, higher blood levels predicted more heart failure, strokes, and cardiovascular deaths over subsequent years. The association remained after accounting for standard risk factors.

This is an established clinical marker for evaluating possible heart failure and assessing prognosis after diagnosis. Its use for prevention is more selective: guidelines support screening people at increased risk when the result leads to appropriate evaluation and follow-up care. The benefit of routinely screening healthy adults at low risk hasn't been established.

Where It Comes From and What It Tracks

Heart muscle cells make a larger protein called proBNP, especially when the heart's walls are stretched. Processing this protein produces BNP and NT-proBNP. BNP is an active hormone that helps blood vessels relax and the kidneys release salt and water. NT-proBNP has no established hormone activity.

NT-proBNP remains in the circulation longer than BNP. Its concentration reflects how much is produced and released, how the parent protein is processed, and how quickly the fragment is removed. Kidney function affects that removal, so the number is an indirect measure of heart strain.

Pressure or fluid overload can come from a weakened heart, impaired filling, valve disease, or an abnormal rhythm. The test reports the blood concentration in pg/mL. It doesn't identify which of these problems is responsible.

Heart Failure Risk

Heart failure can involve weak pumping, difficulty filling, or both. Ejection fraction is the proportion of blood the main pumping chamber ejects with each beat. Heart failure with reduced ejection fraction involves reduced pumping strength. Heart failure with preserved ejection fraction can involve high filling pressures despite a preserved proportion being pumped out.

In a pooled analysis of 41,427 adults from nine cohorts followed for about 11 years, each doubling of NT-proBNP was associated with about 47% higher risk of developing heart failure. Adding it to standard risk factors improved prediction. That establishes useful risk information, though it doesn't by itself prove that testing everyone improves health.

The marker also predicts outcomes in established heart failure. Among 3,480 participants with preserved ejection fraction in the I-PRESERVE trial, those above the group's median NT-proBNP had about 80% higher risk of death or cardiovascular hospitalization than those below it.

In an analysis of people with reduced ejection fraction, reaching the study's lower NT-proBNP target during treatment was associated with about three-quarters lower risk of subsequent heart failure hospitalization or cardiovascular death. This was a comparison between treatment responders and nonresponders, so the difference cannot be attributed entirely to lowering the marker.

Death From Heart Disease and Other Causes

A meta-analysis of 11 general-population studies involving 25,715 adults found that people in the highest NT-proBNP categories had about 2.4 times the risk of dying from any cause compared with those in the lowest categories. The corresponding risks were about 3.8 times higher for cardiovascular death and 2.35 times higher for coronary heart disease death. The categories and follow-up periods differed between studies.

A nationally representative study of 10,645 US adults followed for a median of 17.3 years also linked higher NT-proBNP to cardiovascular and all-cause death.

In the ARIC study, adults without diagnosed cardiovascular disease in the highest NT-proBNP category had long-term cardiovascular risk comparable to or greater than adults with established cardiovascular disease. That finding concerned a selected high-level group. It doesn't establish that every mildly raised result carries the same risk as a known heart condition.

Stroke

Higher NT-proBNP is associated with stroke, especially strokes caused by clots that form in the heart and travel to the brain. These are called cardioembolic strokes. Atrial fibrillation can contribute to both higher NT-proBNP and this type of stroke. It is an irregular heart rhythm that increases the chance of blood clots forming in the heart.

Who Was StudiedWhat Was ComparedWhat They Found
About 1,500 participants selected from the REGARDS cohort, with about 5 years of follow-upHighest quarter of NT-proBNP versus lowest quarterAbout 2.9 times the risk of ischemic stroke and about 9 times the risk of cardioembolic stroke; the latter estimate was imprecise
10,902 ARIC participants followed for about 11 yearsBoth NT-proBNP and troponin T high versus neither highAbout 2.7 times the risk of any stroke and about 6.3 times the risk of cardioembolic stroke
58,173 adults from six European cohorts followed for about 8 yearsHighest quarter of NT-proBNP versus lowest quarterHigher stroke risk, with most recorded strokes caused by blocked blood vessels

These findings support NT-proBNP as a risk marker. They don't establish it as a stand-alone stroke screening test or a basis for prescribing blood thinners. The ARIC comparison also included troponin T, so its effect size cannot be attributed to NT-proBNP alone.

Kidney Disease

NT-proBNP often rises as kidney function falls. Reduced removal contributes, but kidney disease can also increase blood pressure and fluid retention, adding real strain on the heart. Higher NT-proBNP remains associated with mortality across kidney-function groups, so a raised result shouldn't automatically be dismissed as reduced clearance.

In a study of 23,860 people with chronic kidney disease and no heart failure, higher NT-proBNP was associated with faster kidney disease progression in the early and middle stages. This was observational evidence. It doesn't establish NT-proBNP as a replacement for measurements of kidney filtration or urine albumin.

Age, Sex, Race, and Body Weight

The same concentration doesn't carry the same meaning for everyone. Levels generally rise with older age and are higher in women than men during adulthood. National US data also found differences between self-identified racial and ethnic groups.

In the Multi-Ethnic Study of Atherosclerosis, which included 5,597 adults without clinical cardiovascular disease, adjusted NT-proBNP levels were 44% lower in Black participants and 46% lower in Chinese participants than in White participants. These are group averages with substantial overlap between individuals.

Other community research found that the absolute risk associated with a given NT-proBNP concentration differed by sex and racial group. A lower average concentration in a group doesn't establish lower heart failure risk. These findings support considering the rest of your risk profile; they don't provide a validated race-based correction for your individual result.

Obesity also tends to lower NT-proBNP, including in people with heart failure. The explanation is incomplete and appears to involve changes in peptide production and processing. Increased removal of BNP by fat tissue cannot fully explain the finding because NT-proBNP isn't removed through the same peptide-clearance receptor.

This matters most when evaluating persistent breathlessness. A substantial minority of people with heart failure with preserved ejection fraction have low NT-proBNP, particularly when they have obesity. Studies using pressure measurements during exercise have confirmed heart failure in people whose blood result and resting evaluation were reassuring.

Screening Before Symptoms

The 2022 American heart failure guideline says natriuretic peptide screening can be useful in people at risk when followed by team-based care. The American Diabetes Association's 2026 Standards of Care recommend considering BNP or NT-proBNP screening in adults with diabetes and using echocardiography to evaluate abnormal findings.

The STOP-HF randomized trial tested a screening and collaborative-care program using BNP, a related but different blood measurement. The program reduced the combined outcome of new heart dysfunction or heart failure and reduced emergency cardiovascular hospitalizations. Heart failure alone was uncommon, and the difference in that outcome wasn't statistically reliable.

PONTIAC used NT-proBNP itself to select 300 adults with type 2 diabetes and no known cardiac disease. Participants assigned to intensified specialist care had fewer cardiac hospitalizations or cardiac deaths over two years. This supports a linked testing-and-care strategy in a selected population.

Screening can also lead to additional scans and appointments when the blood result doesn't correspond to heart failure. The trials studied people with risk factors, and their benefits came from the care that followed testing. They don't establish a benefit from measuring NT-proBNP without a plan for interpreting and acting on the result.

When Results Can Be Misleading

A raised result can reflect an acute problem as well as chronic heart disease. Sepsis, severe pneumonia, a pulmonary embolism, and surgery can raise NT-proBNP. A pulmonary embolism is a blood clot in the lungs. These increases may represent temporary heart stress and changes in clearance, so they aren't automatically laboratory errors.

  • Recent surgery: in a study of healthy young adults undergoing noncardiac surgery, NT-proBNP roughly tripled within 18 to 30 hours.
  • Strenuous exercise: a demanding exercise session can temporarily raise NT-proBNP. The size of the change depends on the exercise and the person.
  • Time of day: daily variation has been observed, including an afternoon peak in one study. Its contribution to variation was small in another population study.
  • Starting a beta-blocker: natriuretic peptides can rise early after treatment begins even when the medicine is beneficial over the longer term.
  • Laboratory differences: methods and specimen handling can affect results. An apparent change after switching laboratories may partly reflect a measurement difference.
  • Laboratory interference: uncommon interference can produce a result that doesn't fit your symptoms or other findings. The laboratory can investigate a persistent mismatch.

Sacubitril-valsartan affects BNP and NT-proBNP differently. It blocks neprilysin, an enzyme that breaks down BNP. BNP may therefore rise early in treatment, while NT-proBNP isn't directly affected by blocked breakdown through that enzyme. NT-proBNP is often easier to interpret during treatment initiation, but BNP still carries useful prognostic information.

Major weight loss can change the relationship between this number and heart health. Studies of bariatric surgery found that NT-proBNP could rise despite improvements in heart structure or filling. A higher result after substantial weight loss therefore needs context, and a lower number isn't an unconditional measure of better health.

Tracking Your Trend

Repeated measurements can add information to a single result. In a long-running community study, changes between visits were associated with later heart failure hospitalization and death. In established heart failure, falling levels often accompany improvement and lower subsequent risk.

There is still meaningful fluctuation within the same person. Studies of stable heart failure and dialysis populations have reported different amounts of natural variability. No single percentage change reliably distinguishes improvement or deterioration in every setting, and trends remain affected by kidney function, heart rhythm, illness, and weight.

A useful prognostic marker isn't automatically a treatment target. In GUIDE-IT, adjusting heart failure treatment to reach an NT-proBNP target did not improve hospitalization or cardiovascular mortality compared with well-managed usual care. The result belongs alongside symptoms, examination findings, imaging, and the treatments already proven to help.

What Moves This Biomarker

Evidence-backed interventions that affect your NT-proBNP level

↓ Decrease
Sacubitril-valsartan treatment for heart failure
Sacubitril-valsartan lowers NT-proBNP in heart failure. In a pooled analysis of two randomized trials after worsening heart failure, the proportional change from baseline was 24% lower with sacubitril-valsartan than with the control treatment, which was enalapril in one trial and valsartan in the other. This is consistent with reduced heart strain.
MedicationStrong Evidence
↓ Decrease
Cardiac resynchronization therapy for eligible heart failure
A pacing device that coordinates ventricular contraction can lower NT-proBNP when delayed electrical activation contributes to heart failure. In CARE-HF, the median difference versus medical therapy alone was 537 pg/mL at 3 months and 567 pg/mL at 18 months, alongside improvements in heart structure and function.
ProcedureStrong Evidence
↓ Decrease
Semaglutide 2.4 mg weekly for obesity-related heart failure with preserved ejection fraction
Semaglutide lowered NT-proBNP by 18% relative to placebo at 52 weeks in the combined STEP-HFpEF program. Reductions were seen across weight-loss categories. That finding supports a favorable effect on heart failure biology but doesn't prove that the effect is independent of weight loss.
MedicationModerate Evidence
↓ Decrease
Structured aerobic training for chronic heart failure
A meta-analysis found that continuous aerobic training lowered NT-proBNP by about 35% compared with control conditions in the trials measuring this outcome. The review included 38 trials and 2,652 participants across several biomarkers. The effect varied between programs and populations.
ExerciseModerate Evidence
↓ Decrease
Higher habitual physical activity in older adulthood
In a community cohort, the most active older adults were about half as likely as the least active to experience a substantial rise in NT-proBNP over time. This describes a smaller upward trajectory, not a demonstrated fall in every active person's result. Other differences between active and inactive participants may explain part of the association.
LifestyleModerate Evidence
↕ Up & Down
Initiation and dose adjustment of evidence-based beta-blocker therapy
Beta-blockers can raise natriuretic peptides early after initiation while improving heart failure over the longer term. In an analysis of treated heart failure, higher beta-blocker doses were associated with a greater likelihood of reaching the study's lower NT-proBNP target by 90 days. The dose-response finding was observational.
MedicationModerate Evidence
↓ Decrease
Empagliflozin 10 mg daily for heart failure with reduced ejection fraction
Empagliflozin lowered NT-proBNP by 13% compared with placebo at 52 weeks in EMPEROR-Reduced. It also improves heart failure outcomes, though the size of the biomarker change doesn't measure the full clinical benefit.
MedicationModest Evidence
↓ Decrease
Spironolactone added to heart failure treatment
In a randomized study of 117 adults with heart failure, adding spironolactone lowered NT-proBNP over 6 months compared with conventional treatment alone. The treatment also improved measures of heart function.
MedicationModest Evidence
↓ Decrease
Reduced dietary sodium in adults with elevated blood pressure
Lower sodium intake reduced NT-proBNP in the DASH-Sodium controlled feeding trial, across the dietary patterns studied. This supports reduced cardiac strain in adults with elevated blood pressure who did not have heart failure.
DietModest Evidence
↓ Decrease
Two grams daily of the fish-oil preparation studied in an elderly heart failure trial
In a small randomized trial of 76 older adults with chronic heart failure, the studied fish-oil preparation lowered plasma NT-proBNP over 3 months compared with placebo. The trial did not establish improved pumping function or fewer clinical events from this biomarker reduction.
SupplementModest Evidence
↓ Decrease
Coenzyme Q10 at 120 mg daily alongside heart failure treatment
A 6-month randomized trial of 120 adults with heart failure found lower NT-proBNP with coenzyme Q10 than with placebo. This provides limited evidence of a favorable biomarker response, but the finding hasn't been consistent across trials and doesn't establish a predictable benefit for an individual.
SupplementModest Evidence
↓ Decrease
Dose adjustment of ACE inhibitor therapy for heart failure
Higher ACE inhibitor doses were associated with a greater likelihood of reaching a lower NT-proBNP during treatment for heart failure with reduced ejection fraction. This is consistent with reduced cardiac strain, but the analysis didn't randomly assign people to different doses.
MedicationModest Evidence

Frequently Asked Questions

NT-proBNP Test

$109
FSA/HSA eligible
No Rx needed
HIPAA compliant